Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis
Strober B, Teller C, Yamauchi P, Miller J, Hooper M, Yang Y, Dann F. Effects of etanercept on C‐reactive protein levels in psoriasis and psoriatic arthritis. British Journal Of Dermatology 2008, 159: 322-330. PMID: 18503600, DOI: 10.1111/j.1365-2133.2008.08628.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, PsoriaticBiomarkersBody Mass IndexC-Reactive ProteinDouble-Blind MethodEtanerceptFemaleHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRetrospective StudiesSeverity of Illness IndexTumor Necrosis Factor-alphaConceptsC-reactive proteinBody mass indexEffect of etanerceptCRP levelsPsoriatic arthritisCRP valuesBaseline C-reactive proteinC-reactive protein levelsHigher body mass indexLower body mass indexBaseline CRP valuesBaseline PASI scoreSkin disease activityStatin drug useSevere plaque psoriasisBaseline CRP levelsElevated CRP levelsSeverity Index scoreEtanercept treatmentRegistrational studiesCRP elevationPlaque psoriasisCardiovascular riskDisease activityPASI score